30 Oct 2020 12:00
Press Release
聽
Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences
聽
聽
Hong Kong, Shanghai, & Florham Park, NJ: Friday, October 30, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:
聽
路 The 15th Citi China Investor Conference on Thursday, November 5, 2020; and
聽
路 The "China Summit Survey Results: Where is the "Bridge to Innovation" Headed?" Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.
聽
Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:
聽
路 The Bank of America 2020 China Conference held from November 2 to 13, 2020;
聽
路 The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020;
聽
路 The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020;
聽
路 The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and
聽
路 The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.
聽
Further information are available at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms."
聽
聽
About Chi-Med
聽
Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
聽
聽
Forward Looking Statements
聽
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
聽
聽
CONTACTS
聽
Investor Enquiries | 聽 |
Mark Lee, Senior Vice President | +852聽2121聽8200 |
Annie Cheng, Vice President | +1聽(973)聽567聽3786 |
聽 | 聽 |
Media Enquiries | 聽 |
Americas - Brad Miles, Solebury Trout | +1聽(917)聽570聽7340聽(Mobile)聽bmiles@troutgroup.com |
Europe - Ben Atwell / Alex Shaw, FTI Consulting | +44聽20聽3727聽1030 / +44聽7771聽913聽902聽(Mobile) / 聽+44聽7779聽545聽055聽(Mobile)Chi-Med@fticonsulting.com |
Asia - Joseph Chi Lo / Zhou Yi, Brunswick | +852聽9850聽5033 (Mobile), jlo@brunswickgroup.com / +852聽9783聽6894聽(Mobile), yzhou@brunswickgroup.com |
聽 | 聽 |
Nominated Advisor | 聽 |
Freddy Crossley / Atholl Tweedie, Panmure聽Gordon聽(UK)聽Limited | +44聽(20)聽7886聽2500 |
聽